Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-16

Unlocking Novel Radiopharmaceutical Targeting Mechanisms
conference in early December
Jeremy Paull will be presenting



Expanding Radiopharmaceutical Targeting Mechanisms with
Novel Moieties to Harness Enhanced Specificity, Efficacy & Safety

The development of novel targeting moieties for radiopharmaceuticals has seen significant
advancements, particularly in the context of targeting cancer cells and supporting tissues. These
novel moieties include small peptides, cyclic peptides, bispecifics and nanobodies, each
offering unique advantages in terms of specificity, stability, and pharmacokinetics.
Uncovering the latest understandings and developments across novel targeting approaches, this
workshop will:

• Exploring DEP Dendrimers as a platform for novel targeting moieties and payloads to achieve
enhanced radioisotope specificity, efficacy and safety

• DEP dendrimers are being used to develop novel targeted radiopharmaceuticals that overcome
delivery challenges to achieve optimal biodistribution, safety and efficacy of radioisotopes.
Exploring in vivo demonstration of the ability of dendrimers to deliver targeted radiotherapies to
achieve favorable imaging and therapeutic outcomes.

Michel Afargan, Head of Drug Development, Starget Pharma
Jeremy Paull, Vice President - Development & Regulatory Affairs, Starpharma